Literature DB >> 32610128

The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection.

Kristen E Pauken1, Jernej Godec2, Pamela M Odorizzi3, Keturah E Brown1, Kathleen B Yates4, Shin Foong Ngiow3, Kelly P Burke5, Seth Maleri1, Shannon M Grande1, Loise M Francisco1, Mohammed-Alkhatim Ali3, Sabrina Imam4, Gordon J Freeman6, W Nicholas Haining7, E John Wherry8, Arlene H Sharpe9.   

Abstract

The PD-1 pathway regulates dysfunctional T cells in chronic infection and cancer, but the role of this pathway during acute infection remains less clear. Here, we demonstrate that PD-1 signals are needed for optimal memory. Mice deficient in the PD-1 pathway exhibit impaired CD8+ T cell memory following acute influenza infection, including reduced virus-specific CD8+ T cell numbers and compromised recall responses. PD-1 blockade during priming leads to similar differences early post-infection but without the defect in memory formation, suggesting that timing and/or duration of PD-1 blockade could be tailored to modulate host responses. Our studies reveal a role for PD-1 as an integrator of CD8+ T cell signals that promotes CD8+ T cell memory formation and suggest PD-1 continues to fine-tune CD8+ T cells after they migrate into non-lymphoid tissues. These findings have important implications for PD-1-based immunotherapy, in which PD-1 inhibition may influence memory responses in patients.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD8(+) T cell; PD-1; PD-L1; PD-L2; acute infection; checkpoint blockade; effector; influenza; memory

Mesh:

Substances:

Year:  2020        PMID: 32610128      PMCID: PMC7377452          DOI: 10.1016/j.celrep.2020.107827

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  61 in total

1.  Low-affinity T cells are programmed to maintain normal primary responses but are impaired in their recall to low-affinity ligands.

Authors:  Karin M Knudson; Nicholas P Goplen; Cody A Cunningham; Mark A Daniels; Emma Teixeiro
Journal:  Cell Rep       Date:  2013-08-08       Impact factor: 9.423

2.  Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection.

Authors:  Tao Wu; Yinghong Hu; Young-Tae Lee; Keith R Bouchard; Alexandre Benechet; Kamal Khanna; Linda S Cauley
Journal:  J Leukoc Biol       Date:  2013-09-04       Impact factor: 4.962

3.  DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination.

Authors:  F Rodriguez; L L An; S Harkins; J Zhang; M Yokoyama; G Widera; J T Fuller; C Kincaid; I L Campbell; J L Whitton
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

4.  T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

Authors:  Enfu Hui; Jeanne Cheung; Jing Zhu; Xiaolei Su; Marcus J Taylor; Heidi A Wallweber; Dibyendu K Sasmal; Jun Huang; Jeong M Kim; Ira Mellman; Ronald D Vale
Journal:  Science       Date:  2017-03-09       Impact factor: 47.728

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  The route of priming influences the ability of respiratory virus-specific memory CD8+ T cells to be activated by residual antigen.

Authors:  Shiki Takamura; Alan D Roberts; Dawn M Jelley-Gibbs; Susan T Wittmer; Jacob E Kohlmeier; David L Woodland
Journal:  J Exp Med       Date:  2010-05-10       Impact factor: 14.307

7.  CD4+ T cell help guides formation of CD103+ lung-resident memory CD8+ T cells during influenza viral infection.

Authors:  Brian J Laidlaw; Nianzhi Zhang; Heather D Marshall; Mathew M Staron; Tianxia Guan; Yinghong Hu; Linda S Cauley; Joe Craft; Susan M Kaech
Journal:  Immunity       Date:  2014-10-09       Impact factor: 31.745

8.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

9.  Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice.

Authors:  Helge Frebel; Veronika Nindl; Reto A Schuepbach; Thomas Braunschweiler; Kirsten Richter; Johannes Vogel; Carsten A Wagner; Dominique Loffing-Cueni; Michael Kurrer; Burkhard Ludewig; Annette Oxenius
Journal:  J Exp Med       Date:  2012-12-10       Impact factor: 14.307

10.  A potential new pathway for PD-L1 costimulation of the CD8-T cell response to Listeria monocytogenes infection.

Authors:  Daqi Xu; Han-Hsuan Fu; Joshua J Obar; Jang-June Park; Koji Tamada; Hideo Yagita; Leo Lefrançois
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

View more
  32 in total

Review 1.  Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved.

Authors:  Edward F Fritsch; Ute E Burkhardt; Nir Hacohen; Catherine J Wu
Journal:  Cancer Immunol Res       Date:  2020-12       Impact factor: 11.151

2.  Decreased expression of programmed death-1 on CD8+ effector memory T lymphocytes correlates with the pathogenesis of type 1 diabetes.

Authors:  Yimei Shan; Yinghong Kong; Yan Zhou; Jingjing Guo; Qiyun Shi; Sicheng Li; Heming Guo; Yiting Huang; Sisi Ding; Cuiping Liu; Lei Cao; Yun Huang; Chen Fang; Ji Hu
Journal:  Acta Diabetol       Date:  2021-04-23       Impact factor: 4.280

Review 3.  Programmed death ligand 1 signals in cancer cells.

Authors:  Anand V R Kornepati; Ratna K Vadlamudi; Tyler J Curiel
Journal:  Nat Rev Cancer       Date:  2022-01-14       Impact factor: 60.716

4.  Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.

Authors:  Annika Fendler; Lewis Au; Scott T C Shepherd; Fiona Byrne; Maddalena Cerrone; Laura Amanda Boos; Karolina Rzeniewicz; William Gordon; Benjamin Shum; Camille L Gerard; Barry Ward; Wenyi Xie; Andreas M Schmitt; Nalinie Joharatnam-Hogan; Georgina H Cornish; Martin Pule; Leila Mekkaoui; Kevin W Ng; Eleanor Carlyle; Kim Edmonds; Lyra Del Rosario; Sarah Sarker; Karla Lingard; Mary Mangwende; Lucy Holt; Hamid Ahmod; Richard Stone; Camila Gomes; Helen R Flynn; Ana Agua-Doce; Philip Hobson; Simon Caidan; Michael Howell; Mary Wu; Robert Goldstone; Margaret Crawford; Laura Cubitt; Harshil Patel; Mike Gavrielides; Emma Nye; Ambrosius P Snijders; James I MacRae; Jerome Nicod; Firza Gronthoud; Robyn L Shea; Christina Messiou; David Cunningham; Ian Chau; Naureen Starling; Nicholas Turner; Liam Welsh; Nicholas van As; Robin L Jones; Joanne Droney; Susana Banerjee; Kate C Tatham; Shaman Jhanji; Mary O'Brien; Olivia Curtis; Kevin Harrington; Shreerang Bhide; Jessica Bazin; Anna Robinson; Clemency Stephenson; Tim Slattery; Yasir Khan; Zayd Tippu; Isla Leslie; Spyridon Gennatas; Alicia Okines; Alison Reid; Kate Young; Andrew J S Furness; Lisa Pickering; Sonia Gandhi; Steve Gamblin; Charles Swanton; Emma Nicholson; Sacheen Kumar; Nadia Yousaf; Katalin A Wilkinson; Anthony Swerdlow; Ruth Harvey; George Kassiotis; James Larkin; Robert J Wilkinson; Samra Turajlic
Journal:  Nat Cancer       Date:  2021-10-27

Review 5.  Gene editing to enhance the efficacy of cancer cell therapies.

Authors:  Tara Murty; Crystal L Mackall
Journal:  Mol Ther       Date:  2021-10-18       Impact factor: 11.454

Review 6.  Emerging concepts in PD-1 checkpoint biology.

Authors:  Kristen E Pauken; James A Torchia; Apoorvi Chaudhri; Arlene H Sharpe; Gordon J Freeman
Journal:  Semin Immunol       Date:  2021-05-15       Impact factor: 11.130

7.  Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.

Authors:  Zhuting Hu; Donna E Leet; Rosa L Allesøe; Giacomo Oliveira; Shuqiang Li; Adrienne M Luoma; Jinyan Liu; Juliet Forman; Teddy Huang; J Bryan Iorgulescu; Rebecca Holden; Siranush Sarkizova; Satyen H Gohil; Robert A Redd; Jing Sun; Liudmila Elagina; Anita Giobbie-Hurder; Wandi Zhang; Lauren Peter; Zoe Ciantra; Scott Rodig; Oriol Olive; Keerthi Shetty; Jason Pyrdol; Mohamed Uduman; Patrick C Lee; Pavan Bachireddy; Elizabeth I Buchbinder; Charles H Yoon; Donna Neuberg; Bradley L Pentelute; Nir Hacohen; Kenneth J Livak; Sachet A Shukla; Lars Rønn Olsen; Dan H Barouch; Kai W Wucherpfennig; Edward F Fritsch; Derin B Keskin; Catherine J Wu; Patrick A Ott
Journal:  Nat Med       Date:  2021-01-21       Impact factor: 53.440

Review 8.  Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.

Authors:  David A Braun; Ziad Bakouny; Laure Hirsch; Ronan Flippot; Eliezer M Van Allen; Catherine J Wu; Toni K Choueiri
Journal:  Nat Rev Clin Oncol       Date:  2021-01-12       Impact factor: 66.675

9.  Inhibitory signaling sustains a distinct early memory CD8+ T cell precursor that is resistant to DNA damage.

Authors:  Jonathan B Johnnidis; Yuki Muroyama; Shin Foong Ngiow; Zeyu Chen; Sasikanth Manne; Zhangying Cai; Shufei Song; Jesse M Platt; Jason M Schenkel; Mohamed Abdel-Hakeem; Jean-Christophe Beltra; Allison R Greenplate; Mohammed-Alkhatim A Ali; Kito Nzingha; Josephine R Giles; Christelle Harly; John Attanasio; Kristen E Pauken; Bertram Bengsch; Michael A Paley; Vesselin T Tomov; Makoto Kurachi; Dario A A Vignali; Arlene H Sharpe; Steven L Reiner; Avinash Bhandoola; F Bradley Johnson; E John Wherry
Journal:  Sci Immunol       Date:  2021-01-15

10.  HER2-antigen-specific humoral immune response in breast cancer lymphocytes transplanted in hu-PBL hIL-4 NOG mice.

Authors:  Yusuke Ohno; Shino Ohshima; Asuka Miyamoto; Fuyuki Kametani; Ryoji Ito; Banri Tsuda; Yukie Kasama; Shunsuke Nakada; Hirofumi Kashiwagi; Toshiro Seki; Atsushi Yasuda; Kiyoshi Ando; Mamoru Ito; Yutaka Tokuda; Yoshie Kametani
Journal:  Sci Rep       Date:  2021-06-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.